|
 |
|
|||||||
|
|||||||||
Diabetes 53:1614-1620, 2004
© 2004 by the American Diabetes Association, Inc.
Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
1 Profil Institut für Stoffwechselforschung, Neuss, Germany
2 Novo Nordisk, Bagsvaerd, Denmark
The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age 38 ± 10 years [mean ± SD], BMI 24 ± 2 kg/m2, HbA1c 7.5 ± 1.2%, diabetes duration 18 ± 9 years) participated in this parallel group comparison. Each subject received four single subcutaneous doses of 0.4 units/kg of either insulin detemir (n = 18), insulin glargine (n = 16), or human NPH insulin (n = 17) under euglycemic glucose clamp conditions (target blood glucose concentration 5.5 mmol/l) on four identical study days. The pharmacodynamic (glucose infusion rates [GIRs]) and pharmacokinetic (serum concentrations of insulin detemir, human insulin, and insulin glargine) properties of the basal insulin preparations were recorded for 24 h postdosing. Insulin detemir was associated with significantly less within-subject variability than both NPH insulin and insulin glargine, as assessed by the coefficient of variation (CV) for the pharmacodynamic end points studied [GIR-AUC(0–12 h) 27% (detemir) vs. 59% (NPH) vs. 46% (glargine); GIR-AUC(0–24 h) 27 vs. 68 vs. 48%; GIRmax 23 vs. 46 vs. 36%; P < 0.001 for all comparisons]. Insulin detemir also provided less within-subject variability in the pharmacokinetic end points: maximal concentration (Cmax) 18 vs. 24 vs. 34%; INS-AUC(0–
) 14 vs. 28 vs. 33%. The results suggest that insulin detemir has a significantly more predictable glucose-lowering effect than both NPH insulin and insulin glargine.
Address correspondence and reprint requests to Tim Heise, MD, Profil Institut für Stoffwechselforschung, Hellersbergstr. 9, D-41460 Neuss, Germany. E-mail: tim.heise{at}profil-research.de
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Porcellati, P. Rossetti, N. R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D. R. Owens, G. B. Bolli, and C. G. Fanelli Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study Diabetes Care, October 1, 2007; 30(10): 2447 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rave, A. de la Pena, F. S. Tibaldi, L. Zhang, B. Silverman, M. Hausmann, L. Heinemann, and D. B. Muchmore AIR Inhaled Insulin in Subjects With Chronic Obstructive Pulmonary Disease: Pharmacokinetics, glucodynamics, safety, and tolerability Diabetes Care, July 1, 2007; 30(7): 1777 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ekstrom, J. Salemyr, I. Zachrisson, C. Carlsson-Skwirut, E. Ortqvist, and P. Bang Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1357 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hassan Hyperglycemia management in the hospital setting Am. J. Health Syst. Pharm., May 15, 2007; 64(10_Supplement_6): S9 - S14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Porcellati, P. Rossetti, N. B. Ricci, S. Pampanelli, E. Torlone, S. H. Campos, A. M. Andreoli, G. B. Bolli, and C. G. Fanelli Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes Diabetes Care, May 1, 2007; 30(5): 1261 - 1263. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jones and M. Patel Insulin detemir: A long-acting insulin product Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2466 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, P. Home, and on behalf of the Levemir Treat-to-Target Study Gro A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schade and V. Valentine Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No. Diabetes Care, June 1, 2006; 29(6): 1453 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
P. Wiesli, C. Schmid, O. Kerwer, C. Nigg-Koch, R. Klaghofer, B. Seifert, G. A. Spinas, and K. Schwegler Acute Psychological Stress Affects Glucose Concentrations in Patients With Type 1 Diabetes Following Food Intake but not in the Fasting State Diabetes Care, August 1, 2005; 28(8): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Plank, M. Bodenlenz, F. Sinner, C. Magnes, E. Gorzer, W. Regittnig, L. A. Endahl, E. Draeger, M. Zdravkovic, and T. R. Pieber A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir Diabetes Care, May 1, 2005; 28(5): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Goldman-Levine and K. W Lee Insulin Detemir--A New Basal Insulin Analog Ann. Pharmacother., March 1, 2005; 39(3): 502 - 507. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |